Columbia researchers have discovered how a genetic defect leads to spinal muscular atrophy, a finding that could lead to a new therapy for a disease that affects 1 in 6,000 children.
Columbia’s researchers have opened a trial of a noninvasive, focused ultrasound approach to open the blood-brain barrier, enabling higher concentrations of an effective drug to enter the brain.
Ottavio Arancio, MD, PhD, of CUMC's Taub Institute, coauthored a paper on a compound that prevents memory loss in a mouse model of Alzheimer's. See Northwestern's news release: http://bit.ly/14Zqwwn
One in 4 stroke survivors suffer from PTSD symptoms within the 1st year post-event, and 1 in 9 experience chronic PTSD more than a year later - results of a study led by Columbia University Medical Center researchers.
Columbia University study looks at the relationship between families with exceptional longevity and cognitive impairment consistent with Alzheimer's disease.
Four research centers including the Center for Stroke Disparities Solutions—a partnership of the New York University Langone Medical Center and Columbia University Medical Center —will develop high-impact culturally tailored interventions aimed at lowering stroke risk among racial and ethnic minorities in the United States.
African-Americans carrying a variant in a cholesterol-processing gene, ABCA7, have double the risk for Alzheimer’s than non-carriers. A new study led by CUMC's Richard Mayeux; first author Christiane Reitz.
African-Americans with Alzheimer’s disease were slightly more likely to have one gene, ABCA7, that is thought to confer risk for the disease. CUMC's Dr. Richard Mayeux led the study.
The largest genome-wide search for Alzheimer’s genes in African-Americans has found that African-Americans with a variant of the ABCA7 gene have almost double the risk of developing late-onset Alzheimer’s disease.